The invention relates to a method of increasing the yield of virus, virus particles, or viral vectors from host cells in a bioreactor. The invention provides a reproducible and robust method and system of determining and controlling the optimal time of infection of host cells using a correlation of process air parameters including Air flow, O.sub.2 flow, and respective trends thereof resulting in increased virus yield.

Disclosed herein are methods, compositions, and kits useful to enhance an immune response against an antigen and to improve vaccine efficacy. The disclosed methods, compositions, and kits may be utilized to improve vaccine immunogenicity and enhance immune protection following subsequent antigen challenges. In some embodiments, the methods include co-administering a blocker of the IFN-I pathway with an antigen that is used as part of a vaccine, such as a viral vaccine.

The present disclosure relates to a method for stimulating tumor antigen-specific immune responses comprising cancer vaccination involving the blockade or inhibition of interferon signaling. In particular, the method comprises administering an inhibitor of interferon signaling and a cancer vaccine comprising a tumor antigen, wherein the inhibitor of interferon signaling is administered before the cancer vaccine.

Provided herein are methods of treating cancer by activating resident memory T cells using one or more antigenic peptides.

The present application relates to a medicine for treating tumors. A novel attenuated oncolytic virus strain is provided by means of a site-directed mutation of a wild-type virus matrix protein M of a vesicular stomatitis virus. On the basis of the attenuated oncolytic virus strain, an oncolytic virus vaccine is provided by inserting an exogenous gene into the attenuated strain. A medicine capable of treating multiple types of tumors is provided by the use of the oncolytic virus vaccine in combination with the immune checkpoint inhibitor.

The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

The invention relates to a polynucleotide encoding a polypeptide based on the minimum region of the Orthoreovirus muNS protein that can form inclusions in the endoplasmic reticulum, and to said polypeptide. The invention also relates to a purification method and a method for detecting interaction between two polypeptides based on the capacity of some regions of the Orthoreovirus muNS protein to incorporate themselves into the inclusions, together with a peptide of interest.

The present disclosure provides compositions and methods useful for preventing and/or treating coronavirus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more coronavirus epitopes, such as, for example, from SARS-Cov-2 spike protein.

The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).

The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).